Talazoparib plus enzalutamide significantly improved overall survival in mCRPC patients, including those with HRR gene mutations. The treatment's safety profile aligns with known data for talazoparib ...

SBRT shows promise in achieving progression-free survival in metastatic RCC without systemic therapy, despite limited high-level data. The absence of phase 3 trials leaves a gap in comparing SBRT ...

F-flotufolastat shows a 69% detection rate for recurrent prostate cancer in patients with PSA levels above 0.2 ng/mL post-prostatectomy. The agent demonstrates a 50% detection rate for PSAs below 0.2 ...

SunRISe-4 targets MIBC patients ineligible for or refusing cisplatin-based chemotherapy, addressing an unmet medical need. The trial evaluates TAR-200 plus cetrelimab and cetrelimab monotherapy, ...

Prostate cancer patients have a higher depression incidence (10%-40%) than the general population (9%). Racial disparities exist in depression diagnosis and treatment ...

Aquablation offers a versatile treatment for BPH, accommodating various prostate sizes and shapes, with a relatively flat learning curve for urologists. Proper patient selection is crucial for ...

The study evaluates Focal One robotic HIFU for BPH, focusing on safety and efficacy in a phase 1/2 trial. Phase 1 determines optimal treatment parameters, while phase 2 expands enrollment to assess ...

Chemotherapy is often selected for aggressive or advanced-stage cancers requiring rapid tumor reduction. Patients with specific genetic mutations may benefit more from targeted therapies than ...

Aquablation with HYDROS is a transurethral water jet procedure for BPH, combining resective and non-resective therapy benefits. The HYDROS system uses AI-powered treatment planning and real-time ...

Chemotherapy, particularly docetaxel, significantly influences the adverse event profile, with common side effects including neutropenia, fatigue, and diarrhea. The ARASENS trial findings align with ...

Combining AR and neuroendocrine marker expressions helps identify metastatic castration-sensitive prostate cancer (mCSPC) patient subgroups with different prognoses. Baseline AR and neuroendocrine ...

Neal Shore, MD, FACS, discusses how the patient profile in the VISION trial, which involved progression on multiple therapies, reflects typical cases for Lutetium-177 treatment, emphasizing the ...